AAV1-caspase gene therapy induced pyroptosis for the treatment of tumors
AssigneeThe General Hospital Corporation
InventorsGary J. Brenner, Xandra O. Breakefield, Giulia Fulci
Life of this patent
Estimating the term…
Abstract
Described herein are compositions and methods for treating, inhibiting, preventing, reducing the severity of and/or reducing the progression of schwannoma, as well as any disease or physiological disease-state in which schwannoma plays a role. The compositions comprise an rAAV vector that includes a caspase-1 gene or a variant thereof and a Schwann cell specific promoter.
Claims20
A recombinant adeno-associated virus (rAAV) vector of serotype AAV1 comprising a caspase-1 gene and a Schwann cell specific promoter.
A method of treating, inhibiting, reducing the severity of and/or reducing the progression of a schwanoma related disease-state in a subject, comprising
- directly administering a therapeutically effective amount of a composition comprising an rAAV vector of serotype AAV1 comprising a caspase-1 gene and a Schwann cell specific promoter to a schwanoma in the subject, thereby treating, inhibiting, reducing the severity of and/or reducing the progression of the disease-state in the subject.
A pharmaceutical composition comprising:
- an rAAV vector of serotype AAV1 comprising a caspase-1 gene and a Schwann cell specific promoter;
- and
- a pharmaceutically acceptable carrier.
A kit comprising a composition comprising an rAAV vector of serotype AAV1 comprising a caspase-1 gene and a Schwann cell specific promoter contained within packaging materials.
Dependencies are inferred from the claim text.